Please select the option that best describes you:
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
Pre-clinical trials suggest tamoxifen further induced DNA chromosomal breakage in DNA-repair deficient cells